Maddi Hebebrand, MC, Associate Editor

Explore the top headlines of the week including innovation in scalp treatment, therapeutic updates in rosacea, and acne vulgaris insights from James Del Rosso, DO.

In an interview with Dermatology Times, Del Rosso shared the latest in the treatment landscape for patients with Darier disease.

A recent study found standard burn assessment tools often fail to accurately evaluate injuries in darker skin tones, leading to misdiagnosis and delays.

Researchers found that PsA patients prioritize fatigue, sleep issues, and uncertainty, often ranking them higher than doctors do.

Del Rosso outlined new and off-label therapies for the disease that he shared in his presentation at Winter Clinical Miami.

In an interview with Dermatology Times, Del Rosso gave insight on off-label therapies that could be used to treat granuloma annulare.

The meta-analysis found that HA fillers enhance skin hydration and glow, but do not significantly impact elasticity.

James Del Rosso, DO, explored the treatment landscape and the importance of regular eye exams for patients with AD.

As a part of his presentation at Winter Clinical Miami, Del Rosso discussed new and emerging therapies for acne vulgaris.

Noor noted patients benefit from in-house injection services, avoiding the inconvenience of traveling to off-site centers.

James Del Rosso, DO, shared insights on existing and upcoming therapies for seborrheic dermatitis.

Explore the top headlines of the week including clinical trial updates, social media hair trends, and expert insights.

QRX003 mimics the LEKTI protein to strengthen skin barriers and alleviate symptoms in patients with Netherton Syndrome.

Understanding urticaria subtypes, from spontaneous to inducible, is key to crafting patient-specific management plans.

AP31, a novel micropeptide, delivers anti-aging and anti-inflammatory benefits, improving skin firmness, lifting, and reducing wrinkles.

In his presentation at Winter Clinical Miami, Del Rosso covered new and emerging therapies as well as successful off-label uses.

Researchers found the combination therapy significantly reduced rosacea severity, with 64% achieving mild or normal status in just 4 weeks.

Jason Hawkes, MD, MS, discusses unmet needs in chronic urticaria care and challenges outdated testing practices.

Fast-acting therapies like remibrutinib bring new hope to patients with chronic urticaria who don’t respond to antihistamines.

A recent study found chronic inflammation in psoriasis may contribute to cognitive decline.

Noor emphasizes that patient access is the primary consideration when deciding to use the buy-and-bill model.

Hawkes combines personal experience and clinical expertise to treat urticaria patients.

Explore the top headlines of the week including the growth of NPs and PAs in the field, clinical trial updates, and advancements in therapy.

Mitragotri's work bridges advanced drug development and skin care for tailored treatments.

The new dosing option offers convenience for those managing plaque psoriasis, PsA, and hidradenitis suppurativa.

Researchers found patients with conditions like asthma or dermatitis are more likely to develop early, severe, and prolonged forms of alopecia areata.

Researchers found emotional resilience can mitigate acne's psychological and social challenges.

Effective PsA management requires balancing clinical goals with patient-reported challenges like fatigue and daily disruptions.

The analysis findings support the potential use of zinc and vitamin D supplementation in managing alopecia areata.

Cemiplimab demonstrated a 68% reduction in recurrence risk for high-risk CSCC in the phase 3 C-POST trial, according to Regeneron’s latest findings.